As regulators settle into 2025, it appears more and more states are proposing bills to allow for psychedelic therapy or the legalization of certain psychedelics.

Colorado House Bill 1063 would make a prescription medication that contains crystalline polymorph psilocybin legal to prescribe, dispense, possess, use, and market in Colorado upon the approval of such a drug by the FDA.

New Hampshire House Bill 528 would legalize the possession, use, purchase, and transportation of psilocybin for individuals aged 21 and older.

New York Assembly Bill 628 proposes the legalization of adult possession of plant- or fungus-based hallucinogens, including DMT, ibogaine, mescaline, psilocybin, and psilocyn, removing these substances from New York’s Schedule I controlled substance list. The bill would also crate legal protections for lawful use.

Virginia Senate Bill 1135 would direct the Board of Pharmacy to create regulations for the use, prescribing, and dispensing of crystalline polymorph psilocybin, based upon approval of a drug product from the FDA and rescheduling from the DEA.

Washington Senate Bill 5201 proposes the Psychedelic Substances Act to regulate psilocybin for therapeutic use. The Department of Health and a Psilocybin Substances Board would oversee therapeutic use, allowing for psilocybin administration in controlled settings by licensed facilitators. This would include a two-year development phase starting in September 2025 with licenses issued late 2027.